Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $39.02: Risk below floor (2.5 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.7/10. Specifically: High short interest: 14%; Elevated put/call ratio: 6.25.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and... Read more
Sell if holding. Engine safety override at $39.02: Risk below floor (2.5 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.7/10. Specifically: High short interest: 14%; Elevated put/call ratio: 6.25. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 6.7/10, moderate confidence.
Passes 5/6 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $39.02: Risk below floor (2.5 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.7/10. Specifically: High short interest: 14%; Elevated put/call ratio: 6.25. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $35.91. Score 6.7/10, moderate confidence.
Take-profit target: $43.35 (+12.3% upside). Prior stop was $35.91. Stop-loss: $35.91.
Risk below floor (2.5 < 3.0).
Indivior Pharmaceuticals, Inc. trades at a P/E of 18.9 (forward 10.8). TrendMatrix value score: 7.8/10. Verdict: Sell.
13 analysts cover INDV with a consensus score of 4.2/5. Average price target: $50.
What does Indivior Pharmaceuticals, Inc. do?Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of...
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.